Why Envista Holdings Stock Is Back in Focus Ahead of Earnings
Envista Holdings (NVST) is coming into focus as the company prepares to report its second quarter 2026 financial results on August 5, alongside a conference call and webcast for investors.
The upcoming release offers fresh insight into how this dental products company, with a market value of about US$4.2b, is currently performing across its Specialty Products & Technologies and Equipment & Consumables segments.
See our latest analysis for Envista Holdings.
Envista Holdings shares trade at US$25.76, with an 18.76% year to date share price return and a 24.32% total shareholder return over one year. The 3 and 5 year total shareholder returns indicate longer term weakness, which suggests that recent momentum is improving off a lower base.
If Envista has you looking more closely at medical technology and equipment, you might also want to see which healthcare stocks harnessing AI are gaining attention through the Simply Wall St screener for 40 healthcare AI stocks
Envista Holdings has shown fresh share price momentum and runs a sizeable dental platform, but a solid business does not always mean the stock is on sale. So how does its current valuation stack up today?
Most Popular Narrative: 13.2% Undervalued
Envista Holdings last closed at $25.76, while the most followed narrative points to a fair value of about $29.69, framing the stock as modestly undervalued based on its modeled future earnings and cash flows.
The analysts have a consensus price target of $29.69 for Envista Holdings based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $35.0, and the most bearish reporting a price target of just $21.0.
Curious what earnings path and margin profile sit behind that gap to fair value? The key assumptions combine steady revenue progress, rising profitability and a premium future earnings multiple. Want to see how those pieces fit together in the full Envista narrative?
Result: Fair Value of $29.69 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Envista Holdings still faces risks, including China’s volume based procurement pressure and tariff related cost headwinds that could challenge the current undervalued narrative.
Find out about the key risks to this Envista Holdings narrative.
Another View: Envista Holdings Through the P/E Lens
While the Envista Holdings narrative points to a fair value above the current share price, the P/E picture is less forgiving. At about 61.9x earnings, the stock trades well above the US Medical Equipment industry on 26.8x and a fair ratio of 31.3x. This implies meaningful valuation risk if sentiment cools. How comfortable are you paying a premium multiple for a company still proving out its profit profile?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Interested in whether the cautious tone or the improving sentiment around Envista Holdings feels more convincing to you? Take a closer look at the numbers, stress test the assumptions, and then review the 3 key rewards.
Looking for more Envista Holdings sized investment ideas?
If Envista Holdings has sharpened your interest, do not stop here. Use the Simply Wall St stock screener to uncover other opportunities that might fit your portfolio.
- Target robust cash generators with steady balance sheets by scanning companies through the solid balance sheet and fundamentals stocks screener (47 results).
- Spot potential bargains that the market may be overlooking by checking the 44 high quality undervalued stocks.
- Pursue growth potential that is flying under the radar by reviewing the screener containing 19 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com